{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:03:08Z","timestamp":1788825788797,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01544-6","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:38:00Z","timestamp":1761413880000},"page":"293-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase\u00a04 Randomized Clinical Trial at Week\u00a016"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05969223","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-0100","authenticated-orcid":false,"given":"Eingun James","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Michael","family":"Lewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Ezra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Anschutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton","family":"Bialik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arathi R.","family":"Setty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"5","key":"1544_CR1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/sj.jid.5701140","volume":"128","author":"RL Smith","year":"2008","unstructured":"Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol. 2008;128(5):1325\u20137.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1544_CR2","first-page":"220","volume":"16","author":"M Zhang","year":"2017","unstructured":"Zhang M, Carter C, Olson WH, et al. Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol. 2017;16(3):220\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1544_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjd.17147","volume":"180","author":"M Larsabal","year":"2019","unstructured":"Larsabal M, Ly S, Sbidian E, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180(3):647\u201356.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1544_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358\u201365.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1544_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3.","journal-title":"BMC Dermatol"},{"issue":"5","key":"1544_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"1544_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","volume":"29","author":"KAP Meeuwis","year":"2018","unstructured":"Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatol Treat. 2018;29(8):754\u201360.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1544_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","volume":"60","author":"CS Chan","year":"2009","unstructured":"Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"1544_CR9","unstructured":"National Psoriasis Foundation. Genital Psoriasis Quick Guide. https:\/\/www.psoriasis.org\/genitals\/. Accessed 5 June 25."},{"key":"1544_CR10","unstructured":"National Psoriasis Foundation. Scalp Psoriasis Quick Guide. https:\/\/www.psoriasis.org\/scalp\/. Accessed 5 June 25."},{"issue":"2","key":"1544_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2340\/00015555-1885","volume":"95","author":"KA Meeuwis","year":"2015","unstructured":"Meeuwis KA, de Hullu JA, IntHout J, et al. Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis. Acta Derm Venereol. 2015;95(2):211\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1544_CR12","first-page":"309","volume":"150","author":"A Zampieron","year":"2015","unstructured":"Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150(3):309\u201316.","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"1544_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","volume":"72","author":"C Ryan","year":"2015","unstructured":"Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1544_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1544_CR15","doi-asserted-by":"publisher","first-page":"2287401","DOI":"10.1080\/09546634.2023.2287401","volume":"35","author":"B Strober","year":"2024","unstructured":"Strober B, Callis DK, Mark L, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatol Treat. 2024;35(1):2287401.","journal-title":"J Dermatol Treat"},{"key":"1544_CR16","doi-asserted-by":"publisher","unstructured":"Amorim GM, Radichewski V, Sponholz ML, Carneiro S. P82 Are nail, scalp and intergluteal cleft psoriasis really risk factors for psoriatic arthritis or are we just repeating previous studies? Br J Dermatol. 2024;191(Suppl_3). https:\/\/doi.org\/10.1093\/bjd\/ljae360.112","DOI":"10.1093\/bjd\/ljae360.112"},{"issue":"10148","key":"1544_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"10198","key":"1544_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"1","key":"1544_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1544_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LF Stein Gold","year":"2023","unstructured":"Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase\u00a0IV study (IMMpulse). Br J Dermatol. 2023;189(5):540\u201352.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1544_CR21","doi-asserted-by":"publisher","first-page":"2220849","DOI":"10.1080\/09546634.2023.2220849","volume":"34","author":"D Orsini","year":"2023","unstructured":"Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatol Treat. 2023;34(1):2220849.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1544_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/1346-8138.17659","volume":"52","author":"Y Okubo","year":"2025","unstructured":"Okubo Y, Murakami M, Kobayashi S, et al. Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: results from the randomized, phase\u00a03 JumPPP study. J Dermatol. 2025;52(4):593\u2013602.","journal-title":"J Dermatol"},{"issue":"3","key":"1544_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1544_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00403-021-02200-7","volume":"314","author":"M Megna","year":"2022","unstructured":"Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619\u201323.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1544_CR25","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatol Treat. 2022;33(6):2813\u201320.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"1544_CR26","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, et al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). 2025;15(9):2409\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1544_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13555-017-0212-3","volume":"8","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Kirby B, Ryan C, et al. The development of the GenPs-SFQ to assess the impact of genital psoriasis on sexual health. Dermatol Ther (Heidelb). 2018;8(1):33\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1544_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13555-017-0213-2","volume":"8","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Kirby B, Ryan C, et al. The development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: the genital psoriasis symptoms scale (GPSS). Dermatol Ther (Heidelb). 2018;8(1):45\u201356.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1544_CR29","unstructured":"International Psoriasis Council. Recategorization of Psoriasis Severity. https:\/\/psoriasiscouncil.org\/education\/disease-severity\/. Accessed 5 Dec."},{"key":"1544_CR30","first-page":"41","volume":"8","author":"EJ Yang","year":"2018","unstructured":"Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41\u20137.","journal-title":"Psoriasis (Auckl)"},{"key":"1544_CR31","unstructured":"National Psoriasis Foundation. Impact of Pain and Itch USA 2024. https:\/\/www.psoriasis.org\/advance\/impact-of-pain-and-itch. Accessed 5 Dec."},{"issue":"3","key":"1544_CR32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","volume":"11","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021;11(3):769\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1544_CR33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/09546634.2019.1577546","volume":"30","author":"Y Wang","year":"2019","unstructured":"Wang Y, Coyne K, Sofen H, et al. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J Dermatol Treat. 2019;30(8):775\u201383.","journal-title":"J Dermatol Treat"},{"key":"1544_CR34","first-page":"33","volume":"6","author":"K Blakely","year":"2016","unstructured":"Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33\u201340.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1544_CR35","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2024.07.1521","volume":"91","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Bukhalo M, Stein Gold L, et al. A randomized phase\u00a03b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. J Am Acad Dermatol. 2024;91(6):1150\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1544_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256\u00a0weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024;38(5):864\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1544_CR37","doi-asserted-by":"publisher","first-page":"AB38","DOI":"10.1016\/j.jaad.2024.07.158","volume":"91","author":"LS Gold","year":"2024","unstructured":"Gold LS, Tyring SK, Hong HC, et al. 50251 efficacy of risankizumab versus apremilast among patients with scalp or nail psoriasis from the phase\u00a04 IMMpulse study. J Am Acad Dermatol. 2024;91(3):AB38.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01544-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:24Z","timestamp":1770190824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01544-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01544-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eingun James Song is a consultant, promotional speaker and\/or investigator for AbbVie, Alphyn, Alumis, Amgen, Apogee, Bristol Myers Squibb, CorEvitas, Dermavant, Dermbiont, Galderma, Incyte, Johnson & Johnson, Lilly, LEO, Moon Lake, Novartis, Organon, Ortho dermatologics, Pfize, Regeneron, Sanofi, SUN Pharma, UCB, Veradermics, Takeda, Target Registry Timber. Lindsay Ackerman has been an consultant, speaker, and\/or investigator for AbbVie, Amgen, ArGEN-X, Artacus, AstraZeneca, Biofronterra, Bristol Myers Squibb, Castle, ChemoCentryx, Corevitas (Corrona), DermTech, Eli Lilly, Helsinn Incyte, Janssen, Kyowa Kirin, Mindera, Novartis, Sanofi, Sun, Timber, Trevi, and UCB. Benjamin Ehst is a speaker, adviser and\/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Celldex, Concert, Dermavant, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, LEO, Merck, Navigator Medicines, Novartis, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB, and Ventyx. Phoebe Rich has served on advisory boards for Alumis, Oruka, and Veradermics and as an investigator for Abbvie, Aflasigma, Allakos, Amgen, Arcutis, Aslan, Bristol-Myers-Squibb, Dermavant, Dermbiont, Dermira, EliLilly, Galderma, Hallux, Incyte, Janssen, Leo, Moberg, Pfizer, Sun, Technoderma, Teva, UCB, and Veradermics. Jerry Bagel has received research funds from Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas (Corrona) Psoriasis Registry, Dermavant, Dermira\/UCB, Eli Lilly, Glenmark, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; has served as a consultant for AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; and has served as a speaker for AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis. George Michael Lewitt is a consultant, promotional speaker, and\/or investigator for AbbVie, Amgen, Arcutis, Bristol Meyers Squibb, Dermavant, Galderma Laboratories, Incyte, Janssen, Lilly, Novan, Novartis, Orthodermatologics, Pfizer, Sanofi, Sun Pharma, UCB, and the CorEvitas PsO and AD registries. Navid Ezra is a speaker, adviser and\/or clinical study investigator for AbbVie, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, ChemoCentryx, Dermavant, Eli Lilly, Incyte, Janssen, LEO, Merck, Novartis, Ortho Dermatologics, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB and the CorEvitas registries. Brad Glick is an advisory board member, consultant, speaker and\/or investigator for and received honoraria or grants from Amgen, AbbVie, AstraZeneca, Almirall, Acrutis, Bausch Health\/Valeant, OrthoDermatologics, Boehringer Ingelheim, Bristol Myers Squibb, Brickell Biotech, Cara Therapeutics, ChemoCentryx, Dermavant, Dermira, Eli Lilly, EPI\/Novan Pharmaceuticals, Incyte, Janssen Pharmaceuticals, LEO Pharma, Galderma, Nimbus Lakshmi, Inc, Novartis Pharmaceutical Corporation, Sun Pharma, Pfizer, Sanofi, Regeneron, UCB Biopharmaceuticals and the CorEvitas AD, CorEvitas PSO and PROSE Registries. Dr. Glick is a shareholder of Top MD, LLC. Toni Anschutz, Brenton Bialik, Greg St. John, Arathi Setty, Chenyang Duan, Manish Patel, and Doug Ashley are full time employees of AbbVie receiving a salary and may hold stock and\/or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study approval was obtained from local ethics committees (Advarra, reference numbers available in the supplementary materials), and the patients provided written informed consent for participation in the study and publication of study data. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}